Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 31st Congress of the European Hematology Association (EHA) was held in Stockholm, Sweden, from June 11-14, 2026. This meeting brought together world-leading clinicians and researchers to share cutting-edge updates in the diagnosis, treatment, and management of hematological malignancies and conditions.

EHA 2026

The 31st Congress of the European Hematology Association (EHA)
11–14 June 2026 | Stockholm, Sweden

EHA 2026

The 31st Congress of the European Hematology Association (EHA)
11–14 June 2026 | Stockholm, Sweden
The 31st Congress of the European Hematology Association (EHA) was held in Stockholm, Sweden, from June 11-14, 2026. This meeting brought together world-leading clinicians and researchers to share cutting-edge updates in the diagnosis, treatment, and management of hematological malignancies and conditions.
View all videos

Latest videos

View all
2:18
Phase II atezolizumab shows durable responses in relapsed NK/T-cell lymphoma
Shinichi Makita • 30 Jun 2026
2:06
The evolving role of immunotherapy and frontline treatment strategies in DLBCL
Shinichi Makita • 30 Jun 2026
1:03
Health-related QoL in patients with high-risk APL treated with arsenic trioxide: APOLLO trial
Fabio Efficace • 13 Jun 2026
1:12
Non-biopsy diagnostic strategies for primary CNS lymphoma
Maurilio Ponzoni • 12 Jun 2026

Multiple myeloma

View all
1:32
The future of myeloma therapy: moving toward safer frontline immunotherapy approaches
Fredrik Schjesvold • 11 Jun 2026
3:02
Preserving kidney function in myeloma: impact of melflufen therapy
Fredrik Schjesvold • 11 Jun 2026

Lymphoma

View all
2:18
Phase II atezolizumab shows durable responses in relapsed NK/T-cell lymphoma
Shinichi Makita • 30 Jun 2026
2:06
The evolving role of immunotherapy and frontline treatment strategies in DLBCL
Shinichi Makita • 30 Jun 2026

AML

View all
0:56
Guidance for community oncologists treating patients with relapsed IDH1-mutated AML
Agnieszka Wierzbowska • 12 Jun 2026
1:45
Q-TWiST analysis from the QUANTUM-First trial: evaluating quality-adjusted survival in AML
Esther Oliva • 25 Jun 2026

MPNs

View all
2:01
Reflecting on progress in MPN research and care: a lifetime perspective
Claire Harrison • 13 Jun 2026
1:16
Insights into the evolving treatment paradigm for myelofibrosis beyond spleen and symptom control
Haifa Kathrin Al-Ali • 13 Jun 2026

CLL

View all
2:31
Emerging BTK inhibitor combination strategies being explored in CLL
Alexey Danilov • 13 Jun 2026
1:11
Fixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLL
Paolo Ghia • 11 Jun 2026

MDS

View all
1:55
The future of precision medicine in MDS: genomic profiling and venetoclax-based strategies
Alex Bataller • 8 Jun 2026
2:41
MDS & AML highlights from EHA 2026: secondary myeloid malignancies after CAR-T & menin inhibitors
Ibrahim Yakoub-Agha • 12 Jun 2026

Trial Updates

View all
2:18
Phase II atezolizumab shows durable responses in relapsed NK/T-cell lymphoma
Shinichi Makita • 30 Jun 2026
1:03
Health-related QoL in patients with high-risk APL treated with arsenic trioxide: APOLLO trial
Fabio Efficace • 13 Jun 2026
1:48
Insights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL?
Martin Schrappe • 11 Jun 2026
1:45
Q-TWiST analysis from the QUANTUM-First trial: evaluating quality-adjusted survival in AML
Esther Oliva • 25 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals